CDKN2AIPNL

Across TCGA pan-cancer cohorts, CDKN2AIPNL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDKN2AIPNL data layer compared with 22 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDKN2AIPNL mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CDKN2AIPNL expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where CDKN2AIPNL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.416	0.785	.002	20	view →
LSCC	DFS	Median	III,IV	0.611	0.947	.023	8	view →
CCRCC	DFS	Tertile	II,III,IV	0.644	0.941	.019	8	view →
HNSC	OS	Tertile	IV	0.556	0.904	.005	7	view →
GBM	OS	Median	All	0.629	0.438	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDKN2AIPNL–PDAC (OS)

Open the PDAC breakdown →